2024 Virtual Grand Rounds
2024 Virtual Grand Rounds Session 13: October 9, 2024 - New Conversations in Psoriatic Arthritis: Overcoming Treatment Failure
About
Fall Clinical Virtual Grand Rounds consist of regularly scheduled CME sessions on a variety of dermatological diseases, delivered by the top experts in dermatology. Please join us for this week's session:
Wednesday, October 9, 2024
8 PM ET / 5 PM PT
New Conversations in Psoriatic Arthritis: Overcoming Treatment Failure
This activity is supported by an educational grant from UCB.
Availability
In order to ensure educational material is relevant, educational materials will expire after a certain time period. This course will be available for the following dates:
October 10, 2024
October 10, 2025
Learning Objectives
At the completion of this activity, participants should be better able to:
Discuss the latest clinical and comparative data for new and emerging biologic agents for psoriatic arthritis (PsA)
Identify optimal clinical decision-making approaches for patients with PsA who have not responded to initial biologic therapy
Review strategies for shared decision-making to counsel patients with PsA who have failed previous treatment with biologic therapy
Intended Audience
This activity has been designed for dermatologists, dermatology physician assistants, dermatology nurse practitioners, and other providers involved in the care of patients.
Faculty
Gary Goldenberg, MD
Assistant Clinical Professor of Dermatology
Icahn School of Medicine at Mount Sinai
New York, NY
Bruce Strober, MD, PhD
Clinical Professor of Dermatology Yale University
Department of Dermatology
New Haven, CT
Central Connecticut Dermatology
Cromwell, CT
Ronald Vender, MD, FRCPC
Dermatrials Research Inc & Venderm Consulting
Associate Clinical Professor of Medicine
McMaster University
Hamilton, Canada
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Institute for Continuing Healthcare Education and CMEsquared. The Institute is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement
The Institute for Continuing Healthcare Education designates this live and enduring activity for a maximum of 1 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures & Disclaimers
Disclosures are as follows:
Grant/Research Support: Biofrontera
Consultant: CoolHealth, Cutera, Galderma, Regeneron, Sanofi, Scibase
Speakers’ Bureau or Honoraria: Regeneron Sanofi
Ownership Interest: Verrica
Consultant: AbbVie, Alumis, Almirall, Amgen, Arcutis, Arena, Aristea, Asana, Boehringer Ingelheim, Immunic Therapeutics, Bristol-Myers-Squibb, Connect Biopharma, Dermavant, EPI Health, Evelo Biosciences, Janssen, Leo, Eli Lilly, Maruho, Meiji Seika Pharma, Mindera Health, Novartis, Pfizer, UCB Pharma, Sun Pharma, Regeneron, Sanofi-Genzyme, Union Therapeutics, Ventyxbio, vTv Therapeutics
Speakers’ Bureau or Honoraria: AbbVie, Eli Lilly, Incyte, Janssen, Regeneron, Sanofi-Genzyme
Scientific Co-Director (consulting fee): CorEvitas (formerly Corrona) Psoriasis Registry
Investigator: Dermavant, AbbVie, CorEvitas Psoriasis Registry, Dermira, Cara, Novartis
Editor-in-Chief (honorarium): Journal of Psoriasis and Psoriatic Arthritis
Ownership Interest: Connect Biopharma
Advisory Board/Consultant: AbbVie, Alumis, Amgen, Arcutis, Bausch Health/Valeant, Boehringer Ingelheim, Bristol Myers Squibb, Celltrion, Dermavant
Grant/Research Support: AbbVie, Alumis, Amgen, Arcutis, Bausch Health/Valeant, Boehringer Ingelheim, Bristol Myers Squibb, Celltrion, Dermavant, Dermira
Speaker's Bureau: AbbVie, Alumis, Amgen, Arcutis, Bausch Health/Valeant, Boehringer Ingelheim, Bristol Myers Squibb, Celltrion, Dermavant, Dermira
The Institute discloses that all relevant conflicts have been satisfactorily mitigated.